TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox and is in development as an mpox vaccineNew data show improved tolerability in immunocompromised animals and no evidence of spreading to blood or tissues even at high dosesTonix’s synthetic horsepox vaccine platform has been selected by NIH’s Project NextGen for clinical testingCHATHAM, N.J., Sept.

TNX-801疫苗接种证明了保护动物免受进化枝I猴痘致命攻击的功效，并且正在开发mpox疫苗。新数据显示，免疫功能低下的动物的耐受性得到改善，即使在高剂量下，也没有证据表明会扩散到血液或组织。美国国立卫生研究院的NextGen项目已选择NextGen疫苗平台进行临床测试。新泽西州查塔姆，9月。

09, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced data presented at a symposium hosted by the Department of Medical Microbiology & Immunology and the Li Ka Shing Institute of Virology to celebrate the career and honor the retirement of Tonix’s collaborator, David Evans, Ph.D., FCAHS, Emeritus Professor, Department of Cell Biology, University of Alberta.

2024年9月9日（环球通讯社）--Tonix Pharmaceuticals Holding Corp.（纳斯达克代码：TNXP）（Tonix or the Company），一家完全整合的生物制药公司，拥有上市产品和开发候选人渠道，今天宣布了在由医学微生物学与免疫学系和李嘉诚病毒学研究所主办的研讨会上提供的数据，以庆祝Tonix的合作者David Evans博士，FCAHS，艾伯塔大学细胞生物学系荣誉退休教授的职业生涯和退休。

A copy of the Company’s presentation is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.The presentation titled, “Using Synthetic Biology to Battle Mpox”, detailed the Company’s vaccine platform, led by TNX-801 (horsepox, live virus vaccine for percutaneous administration) for preventing mpox (formerly known as monkeypox).

该公司的演示文稿副本可在Tonix网站www.tonixparma.com的“科学演示”选项卡上找到。标题为“使用合成生物学对抗Mpox”的演示文稿详细介绍了该公司的疫苗平台，该平台由TNX-801（horsepox，用于经皮给药的活病毒疫苗）领导，用于预防Mpox（以前称为猴痘）。

TNX-801 is an attenuated live-virus vaccine based on synthesized horsepox that has been shown to provide single-dose immune protection against a monkeypox challenge with better tolerability than 20th century vaccinia live-virus vaccines in animals.TNX-801 is structurally closer to 19th century live-virus vaccinia vaccines than 20th century versions.

TNX-801是一种基于合成马痘的减毒活病毒疫苗，已被证明可提供针对猴痘攻击的单剂量免疫保护，其耐受性优于20世纪牛痘活病毒疫苗。TNX-801在结构上比20世纪的版本更接近19世纪的活病毒痘苗疫苗。

1-3 Genomic sequencing of archaic smallpox vaccines has shown that vaccines used prior to 1900 would be called ‘horsepox’ today.1-3.

1-3古代天花疫苗的基因组测序表明，1900年之前使用的疫苗今天被称为“马痘”。